Lerdelimumab (also known as CAT-152) is a human monoclonal antibody developed to specifically neutralize transforming growth factor-beta 2 (TGF-β2), one of the predominant isoforms of TGF-β found in the eye. It was designed as a local (intraocular) therapy to prevent the scarring process (fibrosis) that occurs after glaucoma filtration surgery. By blocking TGF-β2, lerdelimumab aimed to inhibit the activation, proliferation, and collagen production of fibroblasts and myofibroblasts at the surgical site, thereby improving surgical outcomes by maintaining an open drainage channel. Although it showed promise in early clinical trials, its development for this indication has been discontinued.